Molecular Mechanisms of Lipid Metabolism Disorders in Infectious Exacerbations of Chronic Obstructive Pulmonary Disease
Abstract
:1. Introduction
2. Lipid Metabolism and Its Disorders in COPD
2.1. The Importance of Lipid Rafts in the Pathogenesis of COPD
2.2. Participation of Lipids in the Regulation of TLR Signaling Pathways
3. Bacterial Infection in the Pathogenesis of Stable Course and Exacerbations of COPD
4. Cross-Links of Lipid Metabolism and Bacterial Infection in the Lungs
5. Participation of Lipids in Phagocytosis Disorders in COPD
6. Participation of Lipids in the Resolution of Inflammation in COPD
7. Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Soriano, J.B.; Kendrick, P.J.; Paulson, K.R.; Gupta, V.; Abrams, E.M.; Adedoyin, R.A.; Adhikari, T.B.; Advani, S.M.; Agrawal, A.; Ahmadian, E.; et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir. Med. 2020, 8, 585–596. [Google Scholar] [CrossRef]
- Quaderi, S.A.; Hurst, J.R. The unmet global burden of COPD. Glob. Health Epidemiol. Genom. 2018, 3, e4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Blanco, I.; Diego, I.; Bueno, P.; Casas-Maldonado, F.; Miravitlles, M. Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps. Eur. Respir. J. 2019, 54, 1900610. [Google Scholar] [CrossRef] [PubMed]
- Lokke, A.; Lange, P.; Lykkegaard, J.; Ibsen, R.; Andersson, M.; de Fine Licht, S.; Hilberg, O. Economic Burden of COPD by Disease Severity—A Nationwide Cohort Study in Denmark. Int. J. Chronic Obs. Pulm. Dis. 2021, 16, 603–613. [Google Scholar] [CrossRef] [PubMed]
- Hashemi, S.Y.; Momenabadi, V.; Faramarzi, A.; Kiani, A. Trends in burden of chronic obstructive pulmonary disease in Iran, 1995–2015: Findings from the global burden of disease study. Arch. Public Health 2020, 78, 45. [Google Scholar] [CrossRef] [PubMed]
- Çolak, Y.; Afzal, S.; Nordestgaard, B.G.; Vestbo, J.; Lange, P. Prevalence, Characteristics, and Prognosis of Early Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am. J. Respir. Crit. Care Med. 2020, 201, 671–680. [Google Scholar] [CrossRef] [PubMed]
- Viniol, C.; Vogelmeier, C.F. Exacerbations of COPD. Eur. Respir. Rev. 2018, 27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Celli, B.R.; MacNee, W. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur. Respir. J. 2004, 23, 932–946. [Google Scholar] [CrossRef] [Green Version]
- Papi, A.; Luppi, F.; Franco, F.; Fabbri, L.M. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2006, 3, 245–251. [Google Scholar] [CrossRef]
- Çolak, Y.; Afzal, S.; Marott, J.L.; Nordestgaard, B.G.; Vestbo, J.; Ingebrigtsen, T.S.; Lange, P. Prognosis of COPD depends on severity of exacerbation history: A population-based analysis. Respir. Med. 2019, 155, 141–147. [Google Scholar] [CrossRef]
- Brill, S.; Jones, T.; Brown, J.; Hurst, J.; Vancheeswaran, R. COPD exacerbation phenotypes in a five year hospitalisation cohort. Eur. Respir. J. 2018, 52, PA3863. [Google Scholar] [CrossRef]
- Vestbo, J. COPD: Definition and Phenotypes. Clin. Chest Med. 2014, 35, 1–6. [Google Scholar] [CrossRef]
- Mirza, S.; Benzo, R. Chronic Obstructive Pulmonary Disease Phenotypes: Implications for Care. Mayo Clin. Proc. 2017, 92, 1104–1112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hogea, S.-P.; Tudorache, E.; Fildan, A.P.; Fira-Mladinescu, O.; Marc, M.; Oancea, C. Risk factors of chronic obstructive pulmonary disease exacerbations. Clin. Respir. J. 2020, 14, 183–197. [Google Scholar] [CrossRef]
- Bhowmik, A.; Seemungal, T.A.; Sapsford, R.J.; Wedzicha, J.A. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000, 55, 114–120. [Google Scholar] [CrossRef] [Green Version]
- Bouquet, J.; Tabor, D.E.; Silver, J.S.; Nair, V.; Tovchigrechko, A.; Griffin, M.P.; Esser, M.T.; Sellman, B.R.; Jin, H. Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort. Respir. Res. 2020, 21, 77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Beech, A.S.; Lea, S.; Kolsum, U.; Wang, Z.; Miller, B.E.; Donaldson, G.C.; Wedzicha, J.A.; Brightling, C.E.; Singh, D. Bacteria and sputum inflammatory cell counts; a COPD cohort analysis. Respir. Res. 2020, 21, 289. [Google Scholar] [CrossRef]
- Halper-Stromberg, E.; Gillenwater, L.; Cruickshank-Quinn, C.; O’Neal, W.K.; Reisdorph, N.; Petrache, I.; Zhuang, Y.; Labaki, W.W.; Curtis, J.L.; Wells, J.; et al. Bronchoalveolar Lavage Fluid from COPD Patients Reveals More Compounds Associated with Disease than Matched Plasma. Metabolites 2019, 9, 157. [Google Scholar] [CrossRef] [Green Version]
- Agudelo, C.W.; Kumley, B.K.; Area-Gomez, E.; Xu, Y.; Dabo, A.J.; Geraghty, P.; Campos, M.; Foronjy, R.; Garcia-Arcos, I. Decreased surfactant lipids correlate with lung function in chronic obstructive pulmonary disease (COPD). PLoS ONE 2020, 15, e0228279. [Google Scholar] [CrossRef]
- Telenga, E.D.; Hoffmann, R.F.; Ruben, T.K.; Hoonhorst, S.J.; Willemse, B.W.; van Oosterhout, A.J.; Heijink, I.H.; van den Berge, M.; Jorge, L.; Sandra, P.; et al. Untargeted lipidomic analysis in chronic obstructive pulmonary disease. Uncovering sphingolipids. Am. J. Respir. Crit Care Med. 2014, 190, 155–164. [Google Scholar] [CrossRef]
- Ghidoni, R.; Caretti, A.; Signorelli, P. Role of Sphingolipids in the Pathobiology of Lung Inflammation. Mediat. Inflamm. 2015, 2015, 487508. [Google Scholar] [CrossRef] [Green Version]
- Gillenwater, L.A.; Kechris, K.J.; Pratte, K.A.; Reisdorph, N.; Petrache, I.; Labaki, W.W.; O’Neal, W.; Krishnan, J.A.; Ortega, V.E.; DeMeo, D.L.; et al. Metabolomic Profiling Reveals Sex Specific Associations with Chronic Obstructive Pulmonary Disease and Emphysema. Metabolites 2021, 11, 161. [Google Scholar] [CrossRef] [PubMed]
- Madenspacher, J.H.; Draper, D.W.; Smoak, K.A.; Li, H.; Griffiths, G.L.; Suratt, B.T.; Wilson, M.D.; Rudel, L.L.; Fessler, M.B. Dyslipidemia induces opposing effects on intrapulmonary and extrapulmonary host defense through divergent TLR response phenotypes. J. Immunol. 2010, 185, 1660–1669. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Agudelo, C.W.; Samaha, G.; Garcia-Arcos, I. Alveolar lipids in pulmonary disease. A review. Lipids Health Dis. 2020, 19, 122. [Google Scholar] [CrossRef]
- Bernardi, S.; Marcuzzi, A.; Piscianz, E.; Tommasini, A.; Fabris, B. The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases. Int. J. Mol. Sci. 2018, 19, 4058. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Howie, D.; Ten Bokum, A.; Necula, A.S.; Cobbold, S.P.; Waldmann, H. The Role of Lipid Metabolism in T Lymphocyte Differentiation and Survival. Front. Immunol. 2018, 8. [Google Scholar] [CrossRef]
- Fernandez-Ruiz, I.; Puchalska, P.; Narasimhulu, C.A.; Sengupta, B.; Parthasarathy, S. Differential lipid metabolism in monocytes and macrophages: Influence of cholesterol loading. J. Lipid Res. 2016, 57, 574–586. [Google Scholar] [CrossRef] [Green Version]
- Batista-Gonzalez, A.; Vidal, R.; Criollo, A.; Carreño, L.J. New Insights on the Role of Lipid Metabolism in the Metabolic Reprogramming of Macrophages. Front. Immunol. 2020, 10. [Google Scholar] [CrossRef]
- Van den Bossche, J.; O’Neill, L.A.; Menon, D. Macrophage Immunometabolism: Where Are We (Going)? Trends Immunol. 2017, 38, 395–406. [Google Scholar] [CrossRef]
- Remmerie, A.; Scott, C.L. Macrophages and lipid metabolism. Cell. Immunol. 2018, 330, 27–42. [Google Scholar] [CrossRef]
- Izquierdo, E.; Cuevas, V.D.; Fernández-Arroyo, S.; Riera-Borrull, M.; Orta-Zavalza, E.; Joven, J.; Rial, E.; Corbi, A.L.; Escribese, M.M. Reshaping of Human Macrophage Polarization through Modulation of Glucose Catabolic Pathways. J. Immunol. 2015, 195, 2442–2451. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Agarwal, A.R.; Kadam, S.; Brahme, A.; Agrawal, M.; Apte, K.; Narke, G.; Kekan, K.; Madas, S.; Salvi, S. Systemic Immuno-metabolic alterations in chronic obstructive pulmonary disease (COPD). Respir. Res. 2019, 20, 171. [Google Scholar] [CrossRef] [PubMed]
- Angela, M.; Endo, Y.; Asou, H.K.; Yamamoto, T.; Tumes, D.J.; Tokuyama, H.; Yokote, K.; Nakayama, T. Fatty acid metabolic reprogramming via mTOR-mediated inductions of PPARγ directs early activation of T cells. Nat. Commun. 2016, 7, 13683. [Google Scholar] [CrossRef] [PubMed]
- Viola, A.; Munari, F.; Sánchez-Rodríguez, R.; Scolaro, T.; Castegna, A. The Metabolic Signature of Macrophage Responses. Front. Immunol. 2019, 10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gong, J.; Zhao, H.; Liu, T.; Li, L.; Cheng, E.; Zhi, S.; Kong, L.; Yao, H.-W.; Li, J. Cigarette Smoke Reduces Fatty Acid Catabolism, Leading to Apoptosis in Lung Endothelial Cells: Implication for Pathogenesis of COPD. Front. Pharmacol. 2019, 10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ween, M.P.; White, J.B.; Tran, H.B.; Mukaro, V.; Jones, C.; Macowan, M.; Hodge, G.; Trim, P.J.; Snel, M.F.; Hodge, S.J. The role of oxidised self-lipids and alveolar macrophage CD1b expression in COPD. Sci. Rep. 2021, 11, 4106. [Google Scholar] [CrossRef] [PubMed]
- Davies, P.; Sornberger, G.C.; Huber, G.L. The stereology of pulmonary alveolar macrophages after prolonged experimental exposure to tobacco smoke. Lab. Investig. 1977, 37, 297–306. [Google Scholar]
- Hannan, S.E.; Harris, J.O.; Sheridan, N.P.; Patel, J.M. Cigarette smoke alters plasma membrane fluidity of rat alveolar macrophages. Am. Rev. Respir. Dis. 1989, 140, 1668–1673. [Google Scholar] [CrossRef]
- Van der Does, A.M.; Heijink, M.; Mayboroda, O.A.; Persson, L.J.; Aanerud, M.; Bakke, P.; Eagan, T.M.; Hiemstra, P.S.; Giera, M. Dynamic differences in dietary polyunsaturated fatty acid metabolism in sputum of COPD patients and controls. Biochim. Biophys. Acta BBA Mol. Cell Biol. Lipids 2019, 1864, 224–233. [Google Scholar] [CrossRef]
- Van der Does, A.M.; Heijink, M.; Persson, L.J.; Kloos, D.-P.; Aanerud, M.; Bakke, P.; Taube, C.; Eagan, T.; Hiemstra, P.S.; Giera, M. Disturbed fatty acid metabolism in airway secretions of patients with Chronic Obstructive Pulmonary Disease. Eur. Respir. J. 2017, 50, PA3913. [Google Scholar] [CrossRef]
- Das, U.N. Arachidonic acid and other unsaturated fatty acids and some of their metabolites function as endogenous antimicrobial molecules: A review. J. Adv. Res. 2018, 11, 57–66. [Google Scholar] [CrossRef]
- Rutting, S.; Papanicolaou, M.; Xenaki, D.; Wood, L.G.; Mullin, A.M.; Hansbro, P.M.; Oliver, B.G. Dietary ω-6 polyunsaturated fatty acid arachidonic acid increases inflammation, but inhibits ECM protein expression in COPD. Respir. Res. 2018, 19, 211. [Google Scholar] [CrossRef] [Green Version]
- Gutiérrez, S.; Svahn, S.L.; Johansson, M.E. Effects of Omega-3 Fatty Acids on Immune Cells. Int. J. Mol. Sci. 2019, 20, 5028. [Google Scholar] [CrossRef] [Green Version]
- Simons, K.; Gerl, M.J. Revitalizing membrane rafts: New tools and insights. Nat. Rev. Mol. Cell Biol. 2010, 11, 688–699. [Google Scholar] [CrossRef] [PubMed]
- Tsai, Y.-H.; Chen, W.-L. Host Lipid Rafts as the Gates for Listeria monocytogenes Infection: A Mini-Review. Front. Immunol. 2020, 11. [Google Scholar] [CrossRef] [PubMed]
- Sezgin, E.; Levental, I.; Mayor, S.; Eggeling, C. The mystery of membrane organization: Composition, regulation and roles of lipid rafts. Nat. Rev. Mol. Cell Biol. 2017, 18, 361–374. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Simons, K.; Ikonen, E. Functional rafts in cell membranes. Nature 1997, 387, 569–572. [Google Scholar] [CrossRef] [PubMed]
- Ouweneel, A.B.; Thomas, M.J.; Sorci-Thomas, M.G. The ins and outs of lipid rafts: Functions in intracellular cholesterol homeostasis, microparticles, and cell membranes: Thematic Review Series: Biology of Lipid Rafts. J. Lipid Res. 2020, 61, 676–686. [Google Scholar] [CrossRef] [Green Version]
- Fantini, J.; Barrantes, F.J. How cholesterol interacts with membrane proteins: An exploration of cholesterol-binding sites including CRAC, CARC, and tilted domains. Front. Physiol. 2013, 4, 31. [Google Scholar] [CrossRef] [Green Version]
- Fantini, J.; Epand, R.M.; Barrantes, F.J. Cholesterol-Recognition Motifs in Membrane Proteins. Adv. Exp. Med. Biol. 2019, 1135, 3–25. [Google Scholar] [CrossRef]
- Bieberich, E. Sphingolipids and lipid rafts: Novel concepts and methods of analysis. Chem. Phys. Lipids 2018, 216, 114–131. [Google Scholar] [CrossRef]
- Hellwing, C.; Tigistu-Sahle, F.; Fuhrmann, H.; Käkelä, R.; Schumann, J. Lipid composition of membrane microdomains isolated detergent-free from PUFA supplemented RAW264.7 macrophages. J. Cell. Physiol. 2018, 233, 2602–2612. [Google Scholar] [CrossRef]
- Hansen, C.G.; Nichols, B.J. Exploring the caves: Cavins, caveolins and caveolae. Trends Cell Biol. 2010, 20, 177–186. [Google Scholar] [CrossRef] [PubMed]
- Liu, P.; Rudick, M.; Anderson, R.G. Multiple functions of caveolin-1. J. Biol. Chem. 2002, 277, 41295–41298. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Thomas, C.M.; Smart, E.J. Caveolae structure and function. J. Cell. Mol. Med. 2008, 12, 796–809. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jin, Y.; Lee, S.J.; Minshall, R.D.; Choi, A.M. Caveolin-1: A critical regulator of lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 300, L151–L160. [Google Scholar] [CrossRef] [Green Version]
- Zaas, D.W.; Duncan, M.; Rae Wright, J.; Abraham, S.N. The role of lipid rafts in the pathogenesis of bacterial infections. Biochim. Biophys. Acta BBA Mol. Cell Res. 2005, 1746, 305–313. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stan, R.V. Structure of caveolae. Biochim. Biophys. Acta 2005, 1746, 334–348. [Google Scholar] [CrossRef] [Green Version]
- Yu, Q.; Chen, X.; Fang, X.; Chen, Q.; Hu, C. Caveolin-1 aggravates cigarette smoke extract-induced MUC5AC secretion in human airway epithelial cells. Int. J. Mol. Med. 2015, 35, 1435–1442. [Google Scholar] [CrossRef]
- Pike, L.J. Rafts defined: A report on the Keystone Symposium on Lipid Rafts and Cell Function. J. Lipid Res. 2006, 47, 1597–1598. [Google Scholar] [CrossRef] [Green Version]
- Predescu, S.A.; Predescu, D.N.; Malik, A.B. Molecular determinants of endothelial transcytosis and their role in endothelial permeability. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 293, L823–L842. [Google Scholar] [CrossRef] [PubMed]
- Wang, Z.; Tiruppathi, C.; Minshall, R.D.; Malik, A.B. Size and dynamics of caveolae studied using nanoparticles in living endothelial cells. ACS Nano 2009, 3, 4110–4116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Anderson, R.G. The caveolae membrane system. Annu. Rev. Biochem. 1998, 67, 199–225. [Google Scholar] [CrossRef] [Green Version]
- Fielding, C.J.; Fielding, P.E. Relationship between cholesterol trafficking and signaling in rafts and caveolae. Biochim. Biophys. Acta BBA Biomembr. 2003, 1610, 219–228. [Google Scholar] [CrossRef] [Green Version]
- Drab, M.; Verkade, P.; Elger, M.; Kasper, M.; Lohn, M.; Lauterbach, B.; Menne, J.; Lindschau, C.; Mende, F.; Luft, F.C.; et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001, 293, 2449–2452. [Google Scholar] [CrossRef] [Green Version]
- Garrean, S.; Gao, X.P.; Brovkovych, V.; Shimizu, J.; Zhao, Y.Y.; Vogel, S.M.; Malik, A.B. Caveolin-1 regulates NF-kappaB activation and lung inflammatory response to sepsis induced by lipopolysaccharide. J. Immunol. 2006, 177, 4853–4860. [Google Scholar] [CrossRef] [Green Version]
- Epand, R.M.; Sayer, B.G.; Epand, R.F. Caveolin Scaffolding Region and Cholesterol-rich Domains in Membranes. J. Mol. Biol. 2005, 345, 339–350. [Google Scholar] [CrossRef]
- Sohn, J.; Lin, H.; Fritch, M.R.; Tuan, R.S. Influence of cholesterol/caveolin-1/caveolae homeostasis on membrane properties and substrate adhesion characteristics of adult human mesenchymal stem cells. Stem Cell Res. Ther. 2018, 9, 86. [Google Scholar] [CrossRef] [Green Version]
- Kotlyarov, S.; Kotlyarova, A. The Role of ABC Transporters in Lipid Metabolism and the Comorbid Course of Chronic Obstructive Pulmonary Disease and Atherosclerosis. Int. J. Mol. Sci. 2021, 22, 6711. [Google Scholar] [CrossRef]
- Ouimet, M.; Barrett, T.J.; Fisher, E.A. HDL and Reverse Cholesterol Transport. Circ. Res. 2019, 124, 1505–1518. [Google Scholar] [CrossRef]
- Song, W.; Wang, W.; Dou, L.Y.; Wang, Y.; Xu, Y.; Chen, L.F.; Yan, X.W. The implication of cigarette smoking and cessation on macrophage cholesterol efflux in coronary artery disease patients. J. Lipid Res. 2015, 56, 682–691. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sonett, J.; Goldklang, M.; Sklepkiewicz, P.; Gerber, A.; Trischler, J.; Zelonina, T.; Westerterp, M.; Lemaître, V.; Okada, Y.; D’Armiento, J. A critical role for ABC transporters in persistent lung inflammation in the development of emphysema after smoke exposure. FASEB J 2018, 32, 6724–6736. [Google Scholar] [CrossRef]
- Draper, D.W.; Madenspacher, J.H.; Dixon, D.; King, D.H.; Remaley, A.T.; Fessler, M.B. ATP-binding cassette transporter G1 deficiency dysregulates host defense in the lung. Am. J. Respir. Crit. Care Med. 2010, 182, 404–412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Korhonen, J.T.; Olkkonen, V.M.; Lahesmaa, R.; Puolakkainen, M. ABC-cassette transporter 1 (ABCA1) expression in epithelial cells in Chlamydia pneumoniae infection. Microb. Pathog. 2013, 61–62, 57–61. [Google Scholar] [CrossRef] [PubMed]
- Wu, A.; Wojtowicz, K.; Savary, S.; Hamon, Y.; Trombik, T. Do ABC transporters regulate plasma membrane organization? Cell. Mol. Biol. Lett. 2020, 25, 37. [Google Scholar] [CrossRef]
- Chambenoit, O.; Hamon, Y.; Marguet, D.; Rigneault, H.; Rosseneu, M.; Chimini, G. Specific docking of apolipoprotein A-I at the cell surface requires a functional ABCA1 transporter. J. Biol. Chem. 2001, 276, 9955–9960. [Google Scholar] [CrossRef] [Green Version]
- Hamon, Y.; Broccardo, C.; Chambenoit, O.; Luciani, M.F.; Toti, F.; Chaslin, S.; Freyssinet, J.M.; Devaux, P.F.; McNeish, J.; Marguet, D.; et al. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat. Cell Biol. 2000, 2, 399–406. [Google Scholar] [CrossRef]
- Rigot, V.; Hamon, Y.; Chambenoit, O.; Alibert, M.; Duverger, N.; Chimini, G. Distinct sites on ABCA1 control distinct steps required for cellular release of phospholipids. J. Lipid Res. 2002, 43, 2077–2086. [Google Scholar] [CrossRef] [Green Version]
- Alder-Baerens, N.; Müller, P.; Pohl, A.; Korte, T.; Hamon, Y.; Chimini, G.; Pomorski, T.; Herrmann, A. Headgroup-specific exposure of phospholipids in ABCA1-expressing cells. J. Biol. Chem. 2005, 280, 26321–26329. [Google Scholar] [CrossRef] [Green Version]
- Landry, Y.D.; Denis, M.; Nandi, S.; Bell, S.; Vaughan, A.M.; Zha, X. ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J. Biol. Chem. 2006, 281, 36091–36101. [Google Scholar] [CrossRef] [Green Version]
- Zarubica, A.; Plazzo, A.P.; Stöckl, M.; Trombik, T.; Hamon, Y.; MÜller, P.; Pomorski, T.; Herrmann, A.; Chimini, G. Functional implications of the influence of ABCA1 on lipid microenvironment at the plasma membrane: A biophysical study. FASEB J. 2009, 23, 1775–1785. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koseki, M.; Hirano, K.; Masuda, D.; Ikegami, C.; Tanaka, M.; Ota, A.; Sandoval, J.C.; Nakagawa-Toyama, Y.; Sato, S.B.; Kobayashi, T.; et al. Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-alpha secretion in Abca1-deficient macrophages. J. Lipid Res. 2007, 48, 299–306. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McGillicuddy, F.C.; de la Llera Moya, M.; Hinkle, C.C.; Joshi, M.R.; Chiquoine, E.H.; Billheimer, J.T.; Rothblat, G.H.; Reilly, M.P. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009, 119, 1135–1145. [Google Scholar] [CrossRef] [Green Version]
- Faure, K.; Sawa, T.; Ajayi, T.; Fujimoto, J.; Moriyama, K.; Shime, N.; Wiener-Kronish, J.P. TLR4 signaling is essential for survival in acute lung injury induced by virulent Pseudomonas aeruginosa secreting type III secretory toxins. Respir. Res. 2004, 5, 1. [Google Scholar] [CrossRef] [PubMed]
- Basu, S.; Fenton, M.J. Toll-like receptors: Function and roles in lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286, L887–L892. [Google Scholar] [CrossRef]
- Zhang, X.; Shan, P.; Jiang, G.; Cohn, L.; Lee, P.J. Toll-like receptor 4 deficiency causes pulmonary emphysema. J. Clin. Investig. 2006, 116, 3050–3059. [Google Scholar] [CrossRef]
- Zhang, X.; Shan, P.; Qureshi, S.; Homer, R.; Medzhitov, R.; Noble, P.W.; Lee, P.J. Cutting edge: TLR4 deficiency confers susceptibility to lethal oxidant lung injury. J. Immunol. 2005, 175, 4834–4838. [Google Scholar] [CrossRef] [PubMed]
- Sarir, H.; Mortaz, E.; Karimi, K.; Kraneveld, A.D.; Rahman, I.; Caldenhoven, E.; Nijkamp, F.P.; Folkerts, G. Cigarette smoke regulates the expression of TLR4 and IL-8 production by human macrophages. J. Inflamm. 2009, 6, 12. [Google Scholar] [CrossRef] [Green Version]
- Karimi, K.; Sarir, H.; Mortaz, E.; Smit, J.J.; Hosseini, H.; De Kimpe, S.J.; Nijkamp, F.P.; Folkerts, G. Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages. Respir. Res. 2006, 7, 66. [Google Scholar] [CrossRef] [Green Version]
- Ruysschaert, J.M.; Lonez, C. Role of lipid microdomains in TLR-mediated signalling. Biochim. Biophys. Acta 2015, 1848, 1860–1867. [Google Scholar] [CrossRef]
- Kotlyarov, S. Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive Pulmonary Disease. Int. J. Mol. Sci. 2021, 22, 3334. [Google Scholar] [CrossRef] [PubMed]
- Zhu, X.; Owen, J.S.; Wilson, M.D.; Li, H.; Griffiths, G.L.; Thomas, M.J.; Hiltbold, E.M.; Fessler, M.B.; Parks, J.S. Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J. Lipid Res. 2010, 51, 3196–3206. [Google Scholar] [CrossRef] [Green Version]
- Frisdal, E.; Lesnik, P.; Olivier, M.; Robillard, P.; Chapman, M.J.; Huby, T.; Guerin, M.; Le Goff, W. Interleukin-6 protects human macrophages from cellular cholesterol accumulation and attenuates the proinflammatory response. J. Biol. Chem. 2011, 286, 30926–30936. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Castrillo, A.; Joseph, S.B.; Vaidya, S.A.; Haberland, M.; Fogelman, A.M.; Cheng, G.; Tontonoz, P. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell 2003, 12, 805–816. [Google Scholar] [CrossRef]
- Kleinridders, A.; Schenten, D.; Konner, A.C.; Belgardt, B.F.; Mauer, J.; Okamura, T.; Wunderlich, F.T.; Medzhitov, R.; Bruning, J.C. MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab. 2009, 10, 249–259. [Google Scholar] [CrossRef] [Green Version]
- Lee, J.Y.; Sohn, K.H.; Rhee, S.H.; Hwang, D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 2001, 276, 16683–16689. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rogero, M.M.; Calder, P.C. Obesity, Inflammation, Toll-Like Receptor 4 and Fatty Acids. Nutrients 2018, 10, 432. [Google Scholar] [CrossRef] [Green Version]
- Hoshino, K.; Takeuchi, O.; Kawai, T.; Sanjo, H.; Ogawa, T.; Takeda, Y.; Takeda, K.; Akira, S. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J. Immunol. 1999, 162, 3749–3752. [Google Scholar]
- Cantin, A.M. Cellular response to cigarette smoke and oxidants: Adapting to survive. Proc. Am. Thorac. Soc. 2010, 7, 368–375. [Google Scholar] [CrossRef]
- Lundström, S.L.; Balgoma, D.; Wheelock, Å.M.; Haeggström, J.Z.; Dahlén, S.E.; Wheelock, C.E. Lipid mediator profiling in pulmonary disease. Curr. Pharm. Biotechnol. 2011, 12, 1026–1052. [Google Scholar] [CrossRef]
- Petrache, I.; Natarajan, V.; Zhen, L.; Medler, T.R.; Richter, A.T.; Cho, C.; Hubbard, W.C.; Berdyshev, E.V.; Tuder, R.M. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat. Med. 2005, 11, 491–498. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scarpa, M.C.; Baraldo, S.; Marian, E.; Turato, G.; Calabrese, F.; Saetta, M.; Maestrelli, P. Ceramide expression and cell homeostasis in chronic obstructive pulmonary disease. Respiration 2013, 85, 342–349. [Google Scholar] [CrossRef] [Green Version]
- Fischer, H.; Ellström, P.; Ekström, K.; Gustafsson, L.; Gustafsson, M.; Svanborg, C. Ceramide as a TLR4 agonist; a putative signalling intermediate between sphingolipid receptors for microbial ligands and TLR4. Cell. Microbiol. 2007, 9, 1239–1251. [Google Scholar] [CrossRef] [PubMed]
- Svanborg, C.; Frendéus, B.; Godaly, G.; Hang, L.; Hedlund, M.; Wachtler, C. Toll-like receptor signaling and chemokine receptor expression influence the severity of urinary tract infection. J. Infect. Dis. 2001, 183 (Suppl. 1), S61–S65. [Google Scholar] [CrossRef] [Green Version]
- Joseph, C.K.; Wright, S.D.; Bornmann, W.G.; Randolph, J.T.; Kumar, E.R.; Bittman, R.; Liu, J.; Kolesnick, R.N. Bacterial lipopolysaccharide has structural similarity to ceramide and stimulates ceramide-activated protein kinase in myeloid cells. J. Biol. Chem. 1994, 269, 17606–17610. [Google Scholar] [CrossRef]
- Cuschieri, J.; Bulger, E.; Billgrin, J.; Garcia, I.; Maier, R.V. Acid sphingomyelinase is required for lipid Raft TLR4 complex formation. Surg. Infect. 2007, 8, 91–106. [Google Scholar] [CrossRef] [PubMed]
- MacKichan, M.L.; DeFranco, A.L. Role of ceramide in lipopolysaccharide (LPS)-induced signaling. LPS increases ceramide rather than acting as a structural homolog. J. Biol. Chem. 1999, 274, 1767–1775. [Google Scholar] [CrossRef] [Green Version]
- Jin, J.; Zhang, X.; Lu, Z.; Perry, D.M.; Li, Y.; Russo, S.B.; Cowart, L.A.; Hannun, Y.A.; Huang, Y. Acid sphingomyelinase plays a key role in palmitic acid-amplified inflammatory signaling triggered by lipopolysaccharide at low concentrations in macrophages. Am. J. Physiol. Endocrinol. Metab. 2013, 305, E853–E867. [Google Scholar] [CrossRef]
- Jin, J.; Lu, Z.; Li, Y.; Cowart, L.A.; Lopes-Virella, M.F.; Huang, Y. Docosahexaenoic acid antagonizes the boosting effect of palmitic acid on LPS inflammatory signaling by inhibiting gene transcription and ceramide synthesis. PLoS ONE 2018, 13, e0193343. [Google Scholar] [CrossRef] [Green Version]
- Petrusca, D.N.; Gu, Y.; Adamowicz, J.J.; Rush, N.I.; Hubbard, W.C.; Smith, P.A.; Berdyshev, E.V.; Birukov, K.G.; Lee, C.-H.; Tuder, R.M.; et al. Sphingolipid-mediated inhibition of apoptotic cell clearance by alveolar macrophages. J. Biol. Chem. 2010, 285, 40322–40332. [Google Scholar] [CrossRef] [Green Version]
- Sze, M.A.; Hogg, J.C.; Sin, D.D. Bacterial microbiome of lungs in COPD. Int. J. Chronic Obs. Pulm. Dis 2014, 9, 229–238. [Google Scholar] [CrossRef] [Green Version]
- Cookson, W.O.C.M.; Cox, M.J.; Moffatt, M.F. New opportunities for managing acute and chronic lung infections. Nat. Rev. Microbiol. 2018, 16, 111–120. [Google Scholar] [CrossRef] [PubMed]
- Su, Y.-C.; Jalalvand, F.; Thegerström, J.; Riesbeck, K. The Interplay Between Immune Response and Bacterial Infection in COPD: Focus Upon Non-typeable Haemophilus influenzae. Front. Immunol. 2018, 9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Charlson, E.S.; Bittinger, K.; Haas, A.R.; Fitzgerald, A.S.; Frank, I.; Yadav, A.; Bushman, F.D.; Collman, R.G. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am. J. Respir. Crit. Care Med. 2011, 184, 957–963. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dickson, R.P.; Erb-Downward, J.R.; Freeman, C.M.; McCloskey, L.; Falkowski, N.R.; Huffnagle, G.B.; Curtis, J.L. Bacterial Topography of the Healthy Human Lower Respiratory Tract. mBio 2017, 8, e02287-16. [Google Scholar] [CrossRef]
- Erb-Downward, J.R.; Thompson, D.L.; Han, M.K.; Freeman, C.M.; McCloskey, L.; Schmidt, L.A.; Young, V.B.; Toews, G.B.; Curtis, J.L.; Sundaram, B.; et al. Analysis of the lung microbiome in the “healthy” smoker and in COPD. PLoS ONE 2011, 6, e16384. [Google Scholar] [CrossRef] [Green Version]
- Hilty, M.; Burke, C.; Pedro, H.; Cardenas, P.; Bush, A.; Bossley, C.; Davies, J.; Ervine, A.; Poulter, L.; Pachter, L.; et al. Disordered microbial communities in asthmatic airways. PLoS ONE 2010, 5, e8578. [Google Scholar] [CrossRef] [Green Version]
- Charlson, E.S.; Bittinger, K.; Chen, J.; Diamond, J.M.; Li, H.; Collman, R.G.; Bushman, F.D. Assessing bacterial populations in the lung by replicate analysis of samples from the upper and lower respiratory tracts. PLoS ONE 2012, 7, e42786. [Google Scholar] [CrossRef] [Green Version]
- Ubags, N.D.J.; Marsland, B.J. Mechanistic insight into the function of the microbiome in lung diseases. Eur. Respir. J. 2017, 50, 1602467. [Google Scholar] [CrossRef]
- Dickson, R.P.; Erb-Downward, J.R.; Freeman, C.M.; McCloskey, L.; Beck, J.M.; Huffnagle, G.B.; Curtis, J.L. Spatial Variation in the Healthy Human Lung Microbiome and the Adapted Island Model of Lung Biogeography. Ann. Am. Thorac. Soc. 2015, 12, 821–830. [Google Scholar] [CrossRef]
- Venkataraman, A.; Bassis, C.M.; Beck, J.M.; Young, V.B.; Curtis, J.L.; Huffnagle, G.B.; Schmidt, T.M. Application of a neutral community model to assess structuring of the human lung microbiome. mBio 2015, 6, e02284-14. [Google Scholar] [CrossRef] [Green Version]
- Willner, D.; Haynes, M.R.; Furlan, M.; Schmieder, R.; Lim, Y.W.; Rainey, P.B.; Rohwer, F.; Conrad, D. Spatial distribution of microbial communities in the cystic fibrosis lung. ISME J 2012, 6, 471–474. [Google Scholar] [CrossRef] [Green Version]
- Man, W.H.; de Steenhuijsen Piters, W.A.A.; Bogaert, D. The microbiota of the respiratory tract: Gatekeeper to respiratory health. Nat. Rev. Microbiol. 2017, 15, 259–270. [Google Scholar] [CrossRef]
- Huffnagle, G.B.; Dickson, R.P.; Lukacs, N.W. The respiratory tract microbiome and lung inflammation: A two-way street. Mucosal Immunol. 2017, 10, 299–306. [Google Scholar] [CrossRef] [Green Version]
- Leopold, P.L.; O’Mahony, M.J.; Lian, X.J.; Tilley, A.E.; Harvey, B.G.; Crystal, R.G. Smoking is associated with shortened airway cilia. PLoS ONE 2009, 4, e8157. [Google Scholar] [CrossRef] [PubMed]
- Foster, W.M.; Costa, D.L.; Langenback, E.G. Ozone exposure alters tracheobronchial mucociliary function in humans. J. Appl. Physiol. 1987, 63, 996–1002. [Google Scholar] [CrossRef] [PubMed]
- Segal, L.N.; Clemente, J.C.; Tsay, J.-C.J.; Koralov, S.B.; Keller, B.C.; Wu, B.G.; Li, Y.; Shen, N.; Ghedin, E.; Morris, A.; et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat. Microbiol. 2016, 1, 16031. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pragman, A.A.; Lyu, T.; Baller, J.A.; Gould, T.J.; Kelly, R.F.; Reilly, C.S.; Isaacson, R.E.; Wendt, C.H. The lung tissue microbiota of mild and moderate chronic obstructive pulmonary disease. Microbiome 2018, 6, 7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bassis, C.M.; Erb-Downward, J.R.; Dickson, R.P.; Freeman, C.M.; Schmidt, T.M.; Young, V.B.; Beck, J.M.; Curtis, J.L.; Huffnagle, G.B. Analysis of the Upper Respiratory Tract Microbiotas as the Source of the Lung and Gastric Microbiotas in Healthy Individuals. mBio 2015, 6, e00037-15. [Google Scholar] [CrossRef] [Green Version]
- Rivera-Chavez, F.; Winter, S.E.; Lopez, C.A.; Xavier, M.N.; Winter, M.G.; Nuccio, S.P.; Russell, J.M.; Laughlin, R.C.; Lawhon, S.D.; Sterzenbach, T.; et al. Salmonella uses energy taxis to benefit from intestinal inflammation. PLoS Pathog. 2013, 9, e1003267. [Google Scholar] [CrossRef]
- Dickson, R.P.; Erb-Downward, J.R.; Huffnagle, G.B. The role of the bacterial microbiome in lung disease. Expert Rev. Respir. Med. 2013, 7, 245–257. [Google Scholar] [CrossRef] [Green Version]
- Segal, L.N.; Alekseyenko, A.V.; Clemente, J.C.; Kulkarni, R.; Wu, B.; Gao, Z.; Chen, H.; Berger, K.I.; Goldring, R.M.; Rom, W.N.; et al. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. Microbiome 2013, 1, 19. [Google Scholar] [CrossRef] [Green Version]
- Morris, A.; Beck, J.M.; Schloss, P.D.; Campbell, T.B.; Crothers, K.; Curtis, J.L.; Flores, S.C.; Fontenot, A.P.; Ghedin, E.; Huang, L.; et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am. J. Respir. Crit. Care Med. 2013, 187, 1067–1075. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brown, R.L.; Sequeira, R.P.; Clarke, T.B. The microbiota protects against respiratory infection via GM-CSF signaling. Nat. Commun. 2017, 8, 1512. [Google Scholar] [CrossRef] [PubMed]
- Mayhew, D.; Devos, N.; Lambert, C.; Brown, J.R.; Clarke, S.C.; Kim, V.L.; Magid-Slav, M.; Miller, B.E.; Ostridge, K.K.; Patel, R.; et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax 2018, 73, 422–430. [Google Scholar] [CrossRef] [Green Version]
- Molyneaux, P.L.; Mallia, P.; Cox, M.J.; Footitt, J.; Willis-Owen, S.A.; Homola, D.; Trujillo-Torralbo, M.B.; Elkin, S.; Kon, O.M.; Cookson, W.O.; et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013, 188, 1224–1231. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Engel, M.; Endesfelder, D.; Schloter-Hai, B.; Kublik, S.; Granitsiotis, M.S.; Boschetto, P.; Stendardo, M.; Barta, I.; Dome, B.; Deleuze, J.F.; et al. Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome. PLoS ONE 2017, 12, e0180859. [Google Scholar] [CrossRef] [Green Version]
- Tangedal, S.; Aanerud, M.; Grønseth, R.; Drengenes, C.; Wiker, H.G.; Bakke, P.S.; Eagan, T.M. Comparing microbiota profiles in induced and spontaneous sputum samples in COPD patients. Respir. Res. 2017, 18, 164. [Google Scholar] [CrossRef] [Green Version]
- Diao, W.; Shen, N.; Du, Y.; Qian, K.; He, B. Characterization of throat microbial flora in smokers with or without COPD. Int. J. Chronic Obs. Pulm. Dis. 2017, 12, 1933–1946. [Google Scholar] [CrossRef] [Green Version]
- Garcia-Nuñez, M.; Millares, L.; Pomares, X.; Ferrari, R.; Pérez-Brocal, V.; Gallego, M.; Espasa, M.; Moya, A.; Monsó, E. Severity-Related Changes of Bronchial Microbiome in Chronic Obstructive Pulmonary Disease. J. Clin. Microbiol. 2014, 52, 4217–4223. [Google Scholar] [CrossRef] [Green Version]
- Huang, Y.J.; Sethi, S.; Murphy, T.; Nariya, S.; Boushey, H.A.; Lynch, S.V. Airway Microbiome Dynamics in Exacerbations of Chronic Obstructive Pulmonary Disease. J. Clin. Microbiol. 2014, 52, 2813–2823. [Google Scholar] [CrossRef] [Green Version]
- Jubinville, E.; Veillette, M.; Milot, J.; Maltais, F.; Comeau, A.M.; Levesque, R.C.; Duchaine, C. Exacerbation induces a microbiota shift in sputa of COPD patients. PLoS ONE 2018, 13, e0194355. [Google Scholar] [CrossRef]
- Sapey, E.; Stockley, R.A. COPD exacerbations · 2: Aetiology. Thorax 2006, 61, 250–258. [Google Scholar] [CrossRef] [Green Version]
- Celli, B.R.; Barnes, P.J. Exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J. 2007, 29, 1224–1238. [Google Scholar] [CrossRef]
- Chang, C.L.; Sullivan, G.D.; Karalus, N.C.; Mills, G.D.; Mclachlan, J.D.; Hancox, R.J. Predicting early mortality in acute exacerbation of chronic obstructive pulmonary disease using the CURB65 score. Respirology 2011, 16, 146–151. [Google Scholar] [CrossRef] [PubMed]
- Lou, P.; Zhu, Y.; Chen, P.; Zhang, P.; Yu, J.; Zhang, N.; Chen, N.; Zhang, L.; Wu, H.; Zhao, J. Vulnerability, beliefs, treatments and economic burden of chronic obstructive pulmonary disease in rural areas in China: A cross-sectional study. BMC Public Health 2012, 12, 287. [Google Scholar] [CrossRef]
- Rosell, A.; Monsó, E.; Soler, N.; Torres, F.; Angrill, J.; Riise, G.; Zalacaín, R.; Morera, J.; Torres, A. Microbiologic Determinants of Exacerbation in Chronic Obstructive Pulmonary Disease. Arch. Intern. Med. 2005, 165, 891–897. [Google Scholar] [CrossRef] [PubMed]
- Kuwal, A.; Joshi, V.; Dutt, N.; Singh, S.; Agarwal, K.C.; Purohit, G. A Prospective Study of Bacteriological Etiology in Hospitalized Acute Exacerbation of COPD Patients: Relationship with Lung Function and Respiratory Failure. Turk. Thorac. J. 2018, 19, 19–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sethi, S.; Murphy, T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 2008, 359, 2355–2365. [Google Scholar] [CrossRef]
- Wedzicha, J.A.; Seemungal, T.A. COPD exacerbations: Defining their cause and prevention. Lancet 2007, 370, 786–796. [Google Scholar] [CrossRef]
- Ko, F.W.; Chan, K.P.; Hui, D.S.; Goddard, J.R.; Shaw, J.G.; Reid, D.W.; Yang, I.A. Acute exacerbation of COPD. Respirology 2016, 21, 1152–1165. [Google Scholar] [CrossRef] [Green Version]
- Wilkinson, T.M.A.; Aris, E.; Bourne, S.; Clarke, S.C.; Peeters, M.; Pascal, T.G.; Schoonbroodt, S.; Tuck, A.C.; Kim, V.; Ostridge, K.; et al. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. Thorax 2017, 72, 919–927. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, Z.; Bafadhel, M.; Haldar, K.; Spivak, A.; Mayhew, D.; Miller, B.E.; Tal-Singer, R.; Johnston, S.L.; Ramsheh, M.Y.; Barer, M.R.; et al. Lung microbiome dynamics in COPD exacerbations. Eur. Respir. J. 2016, 47, 1082–1092. [Google Scholar] [CrossRef] [Green Version]
- Polverino, E.; Rosales-Mayor, E.; Benegas, M.; Menendez, R.; Alcaraz-Serrano, V.; Ansotegui, E.; Montull, B.; Giron, R.M.; Cisneros, C.; Vendrell, M.; et al. Pneumonic and non-pneumonic exacerbations in bronchiectasis: Clinical and microbiological differences. J. Infect. 2018, 77, 99–106. [Google Scholar] [CrossRef]
- Simpson, J.L.; Baines, K.J.; Horvat, J.C.; Essilfie, A.-T.; Brown, A.C.; Tooze, M.; McDonald, V.M.; Gibson, P.G.; Hansbro, P.M. COPD is characterized by increased detection of Haemophilus influenzae, Streptococcus pneumoniae and a deficiency of Bacillus species. Respirology 2016, 21, 697–704. [Google Scholar] [CrossRef]
- Soler, N.; Torres, A.; Ewig, S.; Gonzalez, J.; Celis, R.; El-Ebiary, M.; Hernandez, C.; Rodriguez-Roisin, R. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am. J. Respir. Crit. Care Med. 1998, 157, 1498–1505. [Google Scholar] [CrossRef]
- Bogaert, D.; van der Valk, P.; Ramdin, R.; Sluijter, M.; Monninkhof, E.; Hendrix, R.; de Groot, R.; Hermans, P.W.M. Host-Pathogen Interaction during Pneumococcal Infection in Patients with Chronic Obstructive Pulmonary Disease. Infect. Immun. 2004, 72, 818–823. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yao, J.; Rock, C.O. How bacterial pathogens eat host lipids: Implications for the development of fatty acid synthesis therapeutics. J. Biol. Chem. 2015, 290, 5940–5946. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fozo, E.M.; Rucks, E.A. The Making and Taking of Lipids: The Role of Bacterial Lipid Synthesis and the Harnessing of Host Lipids in Bacterial Pathogenesis. Adv. Microb. Physiol. 2016, 69, 51–155. [Google Scholar] [CrossRef]
- Hinkel, L.A.; Wargo, M.J. Participation of Bacterial Lipases, Sphingomyelinases, and Phospholipases in Gram-Negative Bacterial Pathogenesis. In Health Consequences of Microbial Interactions with Hydrocarbons, Oils, and Lipids; Goldfine, H., Ed.; Springer International Publishing: Cham, Switzerland, 2020; pp. 181–203. [Google Scholar]
- Sun, Z.; Kang, Y.; Norris, M.H.; Troyer, R.M.; Son, M.S.; Schweizer, H.P.; Dow, S.W.; Hoang, T.T. Blocking phosphatidylcholine utilization in Pseudomonas aeruginosa, via mutagenesis of fatty acid, glycerol and choline degradation pathways, confirms the importance of this nutrient source in vivo. PLoS ONE 2014, 9, e103778. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Son, M.S.; Matthews, W.J., Jr.; Kang, Y.; Nguyen, D.T.; Hoang, T.T. In vivo evidence of Pseudomonas aeruginosa nutrient acquisition and pathogenesis in the lungs of cystic fibrosis patients. Infect. Immun. 2007, 75, 5313–5324. [Google Scholar] [CrossRef] [Green Version]
- Zarzycki-Siek, J.; Norris, M.H.; Kang, Y.; Sun, Z.; Bluhm, A.P.; McMillan, I.A.; Hoang, T.T. Elucidating the Pseudomonas aeruginosa fatty acid degradation pathway: Identification of additional fatty acyl-CoA synthetase homologues. PLoS ONE 2013, 8, e64554. [Google Scholar] [CrossRef] [Green Version]
- Lafont, F.; Van Der Goot, F.G. Bacterial invasion via lipid rafts. Cell. Microbiol. 2005, 7, 613–620. [Google Scholar] [CrossRef]
- Gagliardi, M.C.; Iwabuchi, K.; Lai, C.-H. Editorial: Role of Lipid Rafts in Anti-microbial Immune Response. Front. Immunol. 2021, 12. [Google Scholar] [CrossRef]
- Duncan, M.J.; Shin, J.S.; Abraham, S.N. Microbial entry through caveolae: Variations on a theme. Cell. Microbiol. 2002, 4, 783–791. [Google Scholar] [CrossRef]
- Manes, S.; del Real, G.; Martinez, A.C. Pathogens: Raft hijackers. Nat. Rev. Immunol. 2003, 3, 557–568. [Google Scholar] [CrossRef]
- Shin, J.S.; Abraham, S.N. Co-option of endocytic functions of cellular caveolae by pathogens. Immunology 2001, 102, 2–7. [Google Scholar] [CrossRef] [PubMed]
- Duffney, P.F.; Embong, A.K.; McGuire, C.C.; Thatcher, T.H.; Phipps, R.P.; Sime, P.J. Cigarette smoke increases susceptibility to infection in lung epithelial cells by upregulating caveolin-dependent endocytosis. PLoS ONE 2020, 15, e0232102. [Google Scholar] [CrossRef] [PubMed]
- Zaas, D.W.; Duncan, M.J.; Li, G.; Wright, J.R.; Abraham, S.N. Pseudomonas invasion of type I pneumocytes is dependent on the expression and phosphorylation of caveolin-2. J. Biol. Chem. 2005, 280, 4864–4872. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grassmé, H.; Jendrossek, V.; Riehle, A.; von Kürthy, G.; Berger, J.; Schwarz, H.; Weller, M.; Kolesnick, R.; Gulbins, E. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat. Med. 2003, 9, 322–330. [Google Scholar] [CrossRef] [PubMed]
- Garcia-Medina, R.; Dunne, W.M.; Singh, P.K.; Brody, S.L. Pseudomonas aeruginosa acquires biofilm-like properties within airway epithelial cells. Infect. Immun. 2005, 73, 8298–8305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grassme, H.; Becker, K.A. Bacterial infections and ceramide. Handb. Exp. Pharm. 2013, 305–320. [Google Scholar] [CrossRef]
- Grassmé, H.; Schwarz, H.; Gulbins, E. Molecular mechanisms of ceramide-mediated CD95 clustering. Biochem. Biophys. Res. Commun. 2001, 284, 1016–1030. [Google Scholar] [CrossRef] [PubMed]
- Avota, E.; de Lira, M.N.; Schneider-Schaulies, S. Sphingomyelin Breakdown in T Cells: Role of Membrane Compartmentalization in T Cell Signaling and Interference by a Pathogen. Front. Cell Dev. Biol. 2019, 7, 152. [Google Scholar] [CrossRef] [Green Version]
- Seitz, A.P.; Grassmé, H.; Edwards, M.J.; Pewzner-Jung, Y.; Gulbins, E. Ceramide and sphingosine in pulmonary infections. Biol. Chem. 2015, 396, 611–620. [Google Scholar] [CrossRef]
- Zhang, Y.; Li, X.; Carpinteiro, A.; Gulbins, E. Acid sphingomyelinase amplifies redox signaling in Pseudomonas aeruginosa-induced macrophage apoptosis. J. Immunol. 2008, 181, 4247–4254. [Google Scholar] [CrossRef] [Green Version]
- Kunz, T.C.; Kozjak-Pavlovic, V. Diverse Facets of Sphingolipid Involvement in Bacterial Infections. Front. Cell Dev. Biol. 2019, 7. [Google Scholar] [CrossRef] [Green Version]
- Manago, A.; Becker, K.A.; Carpinteiro, A.; Wilker, B.; Soddemann, M.; Seitz, A.P.; Edwards, M.J.; Grassme, H.; Szabo, I.; Gulbins, E. Pseudomonas aeruginosa pyocyanin induces neutrophil death via mitochondrial reactive oxygen species and mitochondrial acid sphingomyelinase. Antioxid. Redox Signal. 2015, 22, 1097–1110. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ganesan, V.; Perera, M.N.; Colombini, D.; Datskovskiy, D.; Chadha, K.; Colombini, M. Ceramide and activated Bax act synergistically to permeabilize the mitochondrial outer membrane. Apoptosis 2010, 15, 553–562. [Google Scholar] [CrossRef]
- Rolando, M.; Buchrieser, C. A Comprehensive Review on the Manipulation of the Sphingolipid Pathway by Pathogenic Bacteria. Front. Cell Dev. Biol. 2019, 7, 168. [Google Scholar] [CrossRef] [PubMed]
- Huang, H.; Weaver, A.; Wu, E.; Li, Y.; Gao, H.; Fan, W.; Wu, M. Lipid-based signaling modulates DNA repair response and survival against Klebsiella pneumoniae infection in host cells and in mice. Am. J. Respir. Cell Mol. Biol. 2013, 49, 798–807. [Google Scholar] [CrossRef] [Green Version]
- Yuan, K.; Huang, C.; Fox, J.; Gaid, M.; Weaver, A.; Li, G.; Singh, B.B.; Gao, H.; Wu, M. Elevated inflammatory response in caveolin-1-deficient mice with Pseudomonas aeruginosa infection is mediated by STAT3 protein and nuclear factor kappaB (NF-kappaB). J. Biol. Chem. 2011, 286, 21814–21825. [Google Scholar] [CrossRef] [Green Version]
- Bajmoczi, M.; Gadjeva, M.; Alper, S.L.; Pier, G.B.; Golan, D.E. Cystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa. Am. J. Physiol. Cell Physiol. 2009, 297, C263–C277. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gadjeva, M.; Paradis-Bleau, C.; Priebe, G.P.; Fichorova, R.; Pier, G.B. Caveolin-1 modifies the immunity to Pseudomonas aeruginosa. J. Immunol. 2010, 184, 296–302. [Google Scholar] [CrossRef] [PubMed]
- Lin, Y.-C.; Lin, C.-H.; Kuo, C.-Y.; Yang, V.C. ABCA1 modulates the oligomerization and Golgi exit of caveolin-1 during HDL-mediated cholesterol efflux in aortic endothelial cells. Biochem. Biophys. Res. Commun. 2009, 382, 189–195. [Google Scholar] [CrossRef] [PubMed]
- Agassandian, M.; Miakotina, O.L.; Andrews, M.; Mathur, S.N.; Mallampalli, R.K. Pseudomonas aeruginosa and sPLA2 IB stimulate ABCA1-mediated phospholipid efflux via ERK-activation of PPARalpha-RXR. Biochem. J. 2007, 403, 409–420. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ares, M.A.; Sansabas, A.; Rodriguez-Valverde, D.; Siqueiros-Cendon, T.; Rascon-Cruz, Q.; Rosales-Reyes, R.; Jarillo-Quijada, M.D.; Alcantar-Curiel, M.D.; Cedillo, M.L.; Torres, J.; et al. The Interaction of Klebsiella pneumoniae With Lipid Rafts-Associated Cholesterol Increases Macrophage-Mediated Phagocytosis Due to Down Regulation of the Capsule Polysaccharide. Front. Cell. Infect. Microbiol. 2019, 9, 255. [Google Scholar] [CrossRef] [Green Version]
- Cano, V.; March, C.; Insua, J.L.; Aguiló, N.; Llobet, E.; Moranta, D.; Regueiro, V.; Brennan, G.P.; Millán-Lou, M.I.; Martín, C.; et al. Klebsiella pneumoniae survives within macrophages by avoiding delivery to lysosomes. Cell. Microbiol. 2015, 17, 1537–1560. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sharma, L.; Feng, J.; Britto, C.J.; Dela Cruz, C.S. Mechanisms of Epithelial Immunity Evasion by Respiratory Bacterial Pathogens. Front. Immunol. 2020, 11, 91. [Google Scholar] [CrossRef]
- Sahly, H.; Podschun, R.; Oelschlaeger, T.A.; Greiwe, M.; Parolis, H.; Hasty, D.; Kekow, J.; Ullmann, U.; Ofek, I.; Sela, S. Capsule Impedes Adhesion to and Invasion of Epithelial Cells by Klebsiella pneumoniae. Infect. Immun. 2000, 68, 6744–6749. [Google Scholar] [CrossRef] [Green Version]
- Cortés, G.; Alvarez, D.; Saus, C.; Albertí, S. Role of lung epithelial cells in defense against Klebsiella pneumoniae pneumonia. Infect. Immun. 2002, 70, 1075–1080. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bengoechea, J.A.; Sa Pessoa, J. Klebsiella pneumoniae infection biology: Living to counteract host defences. FEMS Microbiol. Rev. 2018, 43, 123–144. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bertuzzi, M.; Hayes, G.E.; Bignell, E.M. Microbial uptake by the respiratory epithelium: Outcomes for host and pathogen. FEMS Microbiol. Rev. 2019, 43, 145–161. [Google Scholar] [CrossRef]
- Chang, D.; Feng, J.; Liu, H.; Liu, W.; Sharma, L.; Dela Cruz, C.S. Differential effects of the Akt pathway on the internalization of Klebsiella by lung epithelium and macrophages. Innate Immun. 2020, 26, 618–626. [Google Scholar] [CrossRef] [PubMed]
- Struve, C.; Krogfelt, K.A. Role of capsule in Klebsiella pneumoniae virulence: Lack of correlation between in vitro and in vivo studies. FEMS Microbiol. Lett. 2003, 218, 149–154. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rendueles, O. Deciphering the role of the capsule of Klebsiella pneumoniae during pathogenesis: A cautionary tale. Mol. Microbiol. 2020, 113, 883–888. [Google Scholar] [CrossRef] [Green Version]
- Baker, L.Y.; Hobby, C.R.; Siv, A.W.; Bible, W.C.; Glennon, M.S.; Anderson, D.M.; Symes, S.J.; Giles, D.K. Pseudomonas aeruginosa responds to exogenous polyunsaturated fatty acids (PUFAs) by modifying phospholipid composition, membrane permeability, and phenotypes associated with virulence. BMC Microbiol. 2018, 18, 117. [Google Scholar] [CrossRef] [Green Version]
- Torreggiani, A.; Tinti, A.; Jurasekova, Z.; Capdevila, M.; Saracino, M.; Foggia, M.D. Structural Lesions of Proteins Connected to Lipid Membrane Damages Caused by Radical Stress: Assessment by Biomimetic Systems and Raman Spectroscopy. Biomolecules 2019, 9, 794. [Google Scholar] [CrossRef] [Green Version]
- Heipieper, H.J.; Meinhardt, F.; Segura, A. The cis-trans isomerase of unsaturated fatty acids in Pseudomonas and Vibrio: Biochemistry, molecular biology and physiological function of a unique stress adaptive mechanism. FEMS Microbiol. Lett. 2003, 229, 1–7. [Google Scholar] [CrossRef] [Green Version]
- Hobby, C.R.; Herndon, J.L.; Morrow, C.A.; Peters, R.E.; Symes, S.J.K.; Giles, D.K. Exogenous fatty acids alter phospholipid composition, membrane permeability, capacity for biofilm formation, and antimicrobial peptide susceptibility in Klebsiella pneumoniae. MicrobiologyOpen 2019, 8, e00635. [Google Scholar] [CrossRef]
- Bailie, M.B.; Standiford, T.J.; Laichalk, L.L.; Coffey, M.J.; Strieter, R.; Peters-Golden, M. Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. J. Immunol. 1996, 157, 5221–5224. [Google Scholar]
- Ricciotti, E.; FitzGerald, G.A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 986–1000. [Google Scholar] [CrossRef] [PubMed]
- Jurado-Martín, I.; Sainz-Mejías, M.; McClean, S. Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int. J. Mol. Sci. 2021, 22, 3128. [Google Scholar] [CrossRef] [PubMed]
- Schaar, V.; de Vries, S.P.W.; Perez Vidakovics, M.L.A.; Bootsma, H.J.; Larsson, L.; Hermans, P.W.M.; Bjartell, A.; Mörgelin, M.; Riesbeck, K. Multicomponent Moraxella catarrhalis outer membrane vesicles induce an inflammatory response and are internalized by human epithelial cells. Cell. Microbiol. 2011, 13, 432–449. [Google Scholar] [CrossRef] [PubMed]
- Bomberger, J.M.; Maceachran, D.P.; Coutermarsh, B.A.; Ye, S.; O’Toole, G.A.; Stanton, B.A. Long-distance delivery of bacterial virulence factors by Pseudomonas aeruginosa outer membrane vesicles. PLoS Pathog. 2009, 5, e1000382. [Google Scholar] [CrossRef] [Green Version]
- Behrens, F.; Funk-Hilsdorf, T.C.; Kuebler, W.M.; Simmons, S. Bacterial Membrane Vesicles in Pneumonia: From Mediators of Virulence to Innovative Vaccine Candidates. Int. J. Mol. Sci. 2021, 22, 3858. [Google Scholar] [CrossRef] [PubMed]
- Oda, M.; Hashimoto, M.; Takahashi, M.; Ohmae, Y.; Seike, S.; Kato, R.; Fujita, A.; Tsuge, H.; Nagahama, M.; Ochi, S.; et al. Role of sphingomyelinase in infectious diseases caused by Bacillus cereus. PLoS ONE 2012, 7, e38054. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.-M.; Rock, C.O. Membrane lipid homeostasis in bacteria. Nat. Rev. Microbiol. 2008, 6, 222–233. [Google Scholar] [CrossRef] [PubMed]
- Aguilar, P.S.; De Mendoza, D. Control of fatty acid desaturation: A mechanism conserved from bacteria to humans. Mol. Microbiol. 2006, 62, 1507–1514. [Google Scholar] [CrossRef]
- Fernández-Calvet, A.; Rodríguez-Arce, I.; Almagro, G.; Moleres, J.; Euba, B.; Caballero, L.; Martí, S.; Ramos-Vivas, J.; Bartholomew, T.L.; Morales, X.; et al. Modulation of Haemophilus influenzae interaction with hydrophobic molecules by the VacJ/MlaA lipoprotein impacts strongly on its interplay with the airways. Sci. Rep. 2018, 8, 6872. [Google Scholar] [CrossRef] [Green Version]
- Gordon, S. Phagocytosis: An Immunobiologic Process. Immunity 2016, 44, 463–475. [Google Scholar] [CrossRef] [Green Version]
- Underhill, D.M.; Goodridge, H.S. Information processing during phagocytosis. Nat. Rev. Immunol. 2012, 12, 492–502. [Google Scholar] [CrossRef] [Green Version]
- Berenson, C.S.; Wrona, C.T.; Grove, L.J.; Maloney, J.; Garlipp, M.A.; Wallace, P.K.; Stewart, C.C.; Sethi, S. Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2006, 174, 31–40. [Google Scholar] [CrossRef] [Green Version]
- Henson, P.M. Cell Removal: Efferocytosis. Annu. Rev. Cell Dev. Biol. 2017, 33, 127–144. [Google Scholar] [CrossRef] [PubMed]
- Birge, R.B.; Boeltz, S.; Kumar, S.; Carlson, J.; Wanderley, J.; Calianese, D.; Barcinski, M.; Brekken, R.A.; Huang, X.; Hutchins, J.T.; et al. Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ. 2016, 23, 962–978. [Google Scholar] [CrossRef] [Green Version]
- Barnes, P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2016, 138, 16–27. [Google Scholar] [CrossRef] [Green Version]
- Russell, R.E.; Culpitt, S.V.; DeMatos, C.; Donnelly, L.; Smith, M.; Wiggins, J.; Barnes, P.J. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2002, 26, 602–609. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Barbers, R.G.; Evans, M.J.; Gong, H., Jr.; Tashkin, D.P. Enhanced alveolar monocytic phagocyte (macrophage) proliferation in tobacco and marijuana smokers. Am. Rev. Respir. Dis. 1991, 143, 1092–1095. [Google Scholar] [CrossRef] [PubMed]
- Bitterman, P.B.; Saltzman, L.E.; Adelberg, S.; Ferrans, V.J.; Crystal, R.G. Alveolar macrophage replication. One mechanism for the expansion of the mononuclear phagocyte population in the chronically inflamed lung. J. Clin. Investig. 1984, 74, 460–469. [Google Scholar] [CrossRef]
- Taylor, A.E.; Finney-Hayward, T.K.; Quint, J.K.; Thomas, C.M.; Tudhope, S.J.; Wedzicha, J.A.; Barnes, P.J.; Donnelly, L.E. Defective macrophage phagocytosis of bacteria in COPD. Eur. Respir. J. 2010, 35, 1039–1047. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berenson, C.S.; Kruzel, R.L.; Eberhardt, E.; Sethi, S. Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. J. Infect. Dis. 2013, 208, 2036–2045. [Google Scholar] [CrossRef] [Green Version]
- Berenson, C.S.; Garlipp, M.A.; Grove, L.J.; Maloney, J.; Sethi, S. Impaired Phagocytosis of Nontypeable Haemophilus influenzae by Human Alveolar Macrophages in Chronic Obstructive Pulmonary Disease. J. Infect. Dis. 2006, 194, 1375–1384. [Google Scholar] [CrossRef] [Green Version]
- Sethi, S.; Murphy, T.F. Bacterial infection in chronic obstructive pulmonary disease in 2000: A state-of-the-art review. Clin. Microbiol. Rev. 2001, 14, 336–363. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Singh, R.; Belchamber, K.B.R.; Fenwick, P.S.; Chana, K.; Donaldson, G.; Wedzicha, J.A.; Barnes, P.J.; Donnelly, L.E.; COPDMAP consortium. Defective monocyte-derived macrophage phagocytosis is associated with exacerbation frequency in COPD. Respir. Res. 2021, 22, 113. [Google Scholar] [CrossRef] [PubMed]
- Ghosh, B.; Gaike, A.H.; Pyasi, K.; Brashier, B.; Das, V.V.; Londhe, J.D.; Juvekar, S.; Shouche, Y.S.; Donnelly, L.E.; Salvi, S.S.; et al. Bacterial load and defective monocyte-derived macrophage bacterial phagocytosis in biomass smoke-related COPD. Eur. Respir. J. 2019, 53. [Google Scholar] [CrossRef] [PubMed]
- Hodge, S.; Hodge, G.; Scicchitano, R.; Reynolds, P.N.; Holmes, M. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol. Cell Biol. 2003, 81, 289–296. [Google Scholar] [CrossRef] [PubMed]
- Ween, M.; Ahern, J.; Carroll, A.; Hodge, G.; Pizzutto, S.; Jersmann, H.; Reynolds, P.; Hodge, S. A small volume technique to examine and compare alveolar macrophage phagocytosis of apoptotic cells and non typeable Haemophilus influenzae (NTHi). J. Immunol. Methods 2016, 429, 7–14. [Google Scholar] [CrossRef] [PubMed]
- Vandivier, R.W.; Henson, P.M.; Douglas, I.S. Burying the dead: The impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 2006, 129, 1673–1682. [Google Scholar] [CrossRef]
- Thayaparan, D.; Shen, P.; Stämpfli, M.R.; Morissette, M.C. Induction of pulmonary antibodies against oxidized lipids in mice exposed to cigarette smoke. Respir. Res. 2016, 17, 97. [Google Scholar] [CrossRef] [Green Version]
- Morissette, M.C.; Shen, P.; Thayaparan, D.; Stämpfli, M.R. Disruption of pulmonary lipid homeostasis drives cigarette smoke-induced lung inflammation in mice. Eur. Respir. J. 2015, 46, 1451–1460. [Google Scholar] [CrossRef] [Green Version]
- Chen, W.; Li, L.; Wang, J.; Zhang, R.; Zhang, T.; Wu, Y.; Wang, S.; Xing, D. The ABCA1-efferocytosis axis: A new strategy to protect against atherosclerosis. Clin. Chim. Acta 2021, 518, 1–8. [Google Scholar] [CrossRef]
- Elbach, P. Composition and synthesis of lipids in resting and phagocytizing leukocytes. J. Exp. Med. 1959, 110, 969–980. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elsbach, P.; Levy, S. Increased synthesis of phospholipid during phagocytosis. J. Clin. Investig. 1968, 47, 2217–2229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Smolen, J.E.; Shohet, S.B. Remodeling of granulocyte membrane fatty acids during phagocytosis. J. Clin. Investig. 1974, 53, 726–734. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fuhrmann, H.; Miles, E.A.; West, A.L.; Calder, P.C. Membrane fatty acids, oxidative burst and phagocytosis after enrichment of P388D1 monocyte/macrophages with essential 18-carbon fatty acids. Ann. Nutr. Metab. 2007, 51, 155–162. [Google Scholar] [CrossRef]
- Schroit, A.J.; Gallily, R. Macrophage fatty acid composition and phagocytosis: Effect of unsaturation on cellular phagocytic activity. Immunology 1979, 36, 199–205. [Google Scholar] [PubMed]
- Gonzalez-Ferrer, S.; Peñaloza, H.F.; Budnick, J.A.; Bain, W.G.; Nordstrom, H.R.; Lee, J.S.; Van Tyne, D. Finding Order in the Chaos: Outstanding Questions in Klebsiella pneumoniae Pathogenesis. Infect. Immun. 2021, 89, e00693-20. [Google Scholar] [CrossRef]
- Jondle, C.N.; Gupta, K.; Mishra, B.B.; Sharma, J. Klebsiella pneumoniae infection of murine neutrophils impairs their efferocytic clearance by modulating cell death machinery. PLoS Pathog. 2018, 14, e1007338. [Google Scholar] [CrossRef] [Green Version]
- Zheng, D.J.; Abou Taka, M.; Heit, B. Role of Apoptotic Cell Clearance in Pneumonia and Inflammatory Lung Disease. Pathogens 2021, 10, 134. [Google Scholar] [CrossRef]
- Lemke, G. How macrophages deal with death. Nat. Rev. Immunol. 2019, 19, 539–549. [Google Scholar] [CrossRef]
- Nagata, S. Apoptosis and Clearance of Apoptotic Cells. Annu. Rev. Immunol. 2018, 36, 489–517. [Google Scholar] [CrossRef]
- Ahn, D.; Prince, A. Participation of Necroptosis in the Host Response to Acute Bacterial Pneumonia. J. Innate Immun. 2017, 9, 262–270. [Google Scholar] [CrossRef] [Green Version]
- Werz, O.; Gerstmeier, J.; Libreros, S.; De la Rosa, X.; Werner, M.; Norris, P.C.; Chiang, N.; Serhan, C.N. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nat. Commun. 2018, 9, 59. [Google Scholar] [CrossRef] [PubMed]
- Haeggström, J.Z.; Funk, C.D. Lipoxygenase and leukotriene pathways: Biochemistry, biology, and roles in disease. Chem. Rev. 2011, 111, 5866–5898. [Google Scholar] [CrossRef] [PubMed]
- Sandhaus, S.; Swick, A.G. Specialized proresolving mediators in infection and lung injury. Biofactors 2021, 47, 6–18. [Google Scholar] [CrossRef]
- Buckley, C.D.; Gilroy, D.W.; Serhan, C.N. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 2014, 40, 315–327. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chiang, N.; Fredman, G.; Bäckhed, F.; Oh, S.F.; Vickery, T.; Schmidt, B.A.; Serhan, C.N. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 2012, 484, 524–528. [Google Scholar] [CrossRef] [Green Version]
- Serhan, C.N.; Chiang, N.; Van Dyke, T.E. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008, 8, 349–361. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Serhan, C.N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014, 510, 92–101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Serhan, C.N.; Levy, B.D. Resolvins in inflammation: Emergence of the pro-resolving superfamily of mediators. J. Clin. Investig. 2018, 128, 2657–2669. [Google Scholar] [CrossRef] [PubMed]
- Thatcher, T.H.; Woeller, C.F.; McCarthy, C.E.; Sime, P.J. Quenching the fires: Pro-resolving mediators, air pollution, and smoking. Pharm. Ther. 2019, 197, 212–224. [Google Scholar] [CrossRef] [PubMed]
- Levy, B.D.; Clish, C.B.; Schmidt, B.; Gronert, K.; Serhan, C.N. Lipid mediator class switching during acute inflammation: Signals in resolution. Nat. Immunol. 2001, 2, 612–619. [Google Scholar] [CrossRef] [PubMed]
- Kantarci, A.; Van Dyke, T.E. Lipoxins in chronic inflammation. Crit. Rev. Oral Biol. Med. 2003, 14, 4–12. [Google Scholar] [CrossRef] [PubMed]
- Chiang, N.; Serhan, C.N. Specialized pro-resolving mediator network: An update on production and actions. Essays Biochem. 2020, 64, 443–462. [Google Scholar] [CrossRef] [PubMed]
- Calder, P.C. n-3 fatty acids, inflammation and immunity: New mechanisms to explain old actions. Proc. Nutr. Soc. 2013, 72, 326–336. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Duvall, M.G.; Levy, B.D. DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation. Eur. J. Pharm. 2016, 785, 144–155. [Google Scholar] [CrossRef] [Green Version]
- Kasuga, K.; Yang, R.; Porter, T.F.; Agrawal, N.; Petasis, N.A.; Irimia, D.; Toner, M.; Serhan, C.N. Rapid appearance of resolvin precursors in inflammatory exudates: Novel mechanisms in resolution. J. Immunol. 2008, 181, 8677–8687. [Google Scholar] [CrossRef] [Green Version]
- Krishnamoorthy, N.; Abdulnour, R.-E.E.; Walker, K.H.; Engstrom, B.D.; Levy, B.D. Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases. Physiol. Rev. 2018, 98, 1335–1370. [Google Scholar] [CrossRef]
- Balta, M.G.; Papathanasiou, E.; Christopoulos, P.F. Specialized Pro-Resolving Mediators as Potential Regulators of Inflammatory Macrophage Responses in COVID-19. Front. Immunol. 2021, 12. [Google Scholar] [CrossRef]
- Decker, C.; Sadhu, S.; Fredman, G. Pro-Resolving Ligands Orchestrate Phagocytosis. Front. Immunol. 2021, 12, 660865. [Google Scholar] [CrossRef]
- Basil, M.C.; Levy, B.D. Specialized pro-resolving mediators: Endogenous regulators of infection and inflammation. Nat. Rev. Immunol. 2016, 16, 51–67. [Google Scholar] [CrossRef] [PubMed]
- Duvall, M.G.; Bruggemann, T.R.; Levy, B.D. Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation. Mol. Asp. Med. 2017, 58, 44–56. [Google Scholar] [CrossRef] [PubMed]
- De Batlle, J.; Sauleda, J.; Balcells, E.; Gómez, F.P.; Méndez, M.; Rodriguez, E.; Barreiro, E.; Ferrer, J.J.; Romieu, I.; Gea, J.; et al. Association between Ω3 and Ω6 fatty acid intakes and serum inflammatory markers in COPD. J. Nutr. Biochem. 2012, 23, 817–821. [Google Scholar] [CrossRef]
- Drozdovszky, O.; Barta, I.; Antus, B. Sputum eicosanoid profiling in exacerbations of chronic obstructive pulmonary disease. Respiration 2014, 87, 408–415. [Google Scholar] [CrossRef]
- Fritscher, L.G.; Post, M.; Rodrigues, M.T.; Silverman, F.; Balter, M.; Chapman, K.R.; Zamel, N. Profile of eicosanoids in breath condensate in asthma and COPD. J. Breath Res. 2012, 6, 026001. [Google Scholar] [CrossRef] [PubMed]
- Bhat, T.A.; Kalathil, S.G.; Miller, A.; Thatcher, T.H.; Sime, P.J.; Thanavala, Y. Specialized Proresolving Mediators Overcome Immune Suppression Induced by Exposure to Secondhand Smoke. J. Immunol. 2020, 205, 3205–3217. [Google Scholar] [CrossRef] [PubMed]
- Bozinovski, S.; Uddin, M.; Vlahos, R.; Thompson, M.; McQualter, J.L.; Merritt, A.S.; Wark, P.A.; Hutchinson, A.; Irving, L.B.; Levy, B.D.; et al. Serum amyloid A opposes lipoxin A4 to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc. Natl. Acad. Sci. USA 2012, 109, 935–940. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, K.-H.; Park, T.S.; Kim, Y.-S.; Lee, J.S.; Oh, Y.-M.; Lee, S.-D.; Lee, S.W. Resolvin D1 prevents smoking-induced emphysema and promotes lung tissue regeneration. Int. J. Chronic Obs. Pulm. Dis. 2016, 11, 1119–1128. [Google Scholar] [CrossRef] [Green Version]
- Hsiao, H.-M.; Sapinoro, R.E.; Thatcher, T.H.; Croasdell, A.; Levy, E.P.; Fulton, R.A.; Olsen, K.C.; Pollock, S.J.; Serhan, C.N.; Phipps, R.P.; et al. A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLoS ONE 2013, 8, e58258. [Google Scholar] [CrossRef] [Green Version]
- Croasdell, A.; Thatcher, T.H.; Kottmann, R.M.; Colas, R.A.; Dalli, J.; Serhan, C.N.; Sime, P.J.; Phipps, R.P. Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015, 309, L888–L901. [Google Scholar] [CrossRef] [Green Version]
- Codagnone, M.; Cianci, E.; Lamolinara, A.; Mari, V.C.; Nespoli, A.; Isopi, E.; Mattoscio, D.; Arita, M.; Bragonzi, A.; Iezzi, M.; et al. Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection. Mucosal Immunol. 2018, 11, 35–49. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Balode, L.; Strazda, G.; Jurka, N.; Kopeika, U.; Kislina, A.; Bukovskis, M.; Beinare, M.; Gardjušina, V.; Taivāns, I. Lipoxygenase-derived arachidonic acid metabolites in chronic obstructive pulmonary disease. Medicina (Kaunas) 2012, 48, 292–298. [Google Scholar] [CrossRef] [PubMed]
- Vance, R.E.; Hong, S.; Gronert, K.; Serhan, C.N.; Mekalanos, J.J. The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase. Proc. Natl. Acad. Sci. USA 2004, 101, 2135–2139. [Google Scholar] [CrossRef] [Green Version]
- Kirschnek, S.; Gulbins, E. Phospholipase A2 functions in Pseudomonas aeruginosa-induced apoptosis. Infect. Immun. 2006, 74, 850–860. [Google Scholar] [CrossRef] [Green Version]
- Starkey, M.; Hickman, J.H.; Ma, L.; Zhang, N.; De Long, S.; Hinz, A.; Palacios, S.; Manoil, C.; Kirisits, M.J.; Starner, T.D.; et al. Pseudomonas aeruginosa rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung. J. Bacteriol. 2009, 191, 3492–3503. [Google Scholar] [CrossRef] [Green Version]
- Deschamps, J.D.; Ogunsola, A.F.; Jameson, J.B., 2nd; Yasgar, A.; Flitter, B.A.; Freedman, C.J.; Melvin, J.A.; Nguyen, J.V.M.H.; Maloney, D.J.; Jadhav, A.; et al. Biochemical and Cellular Characterization and Inhibitor Discovery of Pseudomonas aeruginosa 15-Lipoxygenase. Biochemistry 2016, 55, 3329–3340. [Google Scholar] [CrossRef] [PubMed]
- Azimzadeh, S.; Mirzaie, M.; Jafari, M.; Mehrani, H.; Shariati, P.; Khodabandeh, M. Signaling network of lipids as a comprehensive scaffold for omics data integration in sputum of COPD patients. Biochim. Biophys. Acta BBA Mol. Cell Biol. Lipids 2015, 1851, 1383–1393. [Google Scholar] [CrossRef] [PubMed]
- Miró, O.; Alonso, J.R.; Jarreta, D.; Casademont, J.; Urbano-Márquez, A.; Cardellach, F. Smoking disturbs mitochondrial respiratory chain function and enhances lipid peroxidation on human circulating lymphocytes. Carcinogenesis 1999, 20, 1331–1336. [Google Scholar] [CrossRef] [Green Version]
- Chatterjee, R.; Chowdhury, A.R.; Mukherjee, D.; Chakravortty, D. Lipid larceny: Channelizing host lipids for establishing successful pathogenesis by bacteria. Virulence 2021, 12, 195–216. [Google Scholar] [CrossRef]
- Paulowski, L.; Donoghue, A.; Nehls, C.; Groth, S.; Koistinen, M.; Hagge, S.O.; Böhling, A.; Winterhalter, M.; Gutsmann, T. The Beauty of Asymmetric Membranes: Reconstitution of the Outer Membrane of Gram-Negative Bacteria. Front. Cell Dev. Biol. 2020, 8, 586. [Google Scholar] [CrossRef] [PubMed]
- Kunz, L.I.Z.; ten Hacken, N.H.T.; Lapperre, T.S.; Timens, W.; Kerstjens, H.A.M.; van Schadewijk, A.; Vonk, J.M.; Sont, J.K.; Snoeck-Stroband, J.B.; Postma, D.S.; et al. Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids. Eur. Respir. J. 2017, 49, 1600839. [Google Scholar] [CrossRef] [Green Version]
- Tantucci, C.; Pini, L. Inhaled Corticosteroids in COPD: Trying to Make a Long Story Short. Int. J. Chronic Obs. Pulm. Dis. 2020, 15, 821–829. [Google Scholar] [CrossRef] [Green Version]
- Lee, J.H.; Park, Y.H.; Kang, D.R.; Lee, S.J.; Lee, M.K.; Kim, S.H.; Yong, S.J.; Lee, W.Y. Risk of Pneumonia Associated with Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease: A Korean Population-Based Study. Int. J. Chronic Obs. Pulm. Dis. 2020, 15, 3397–3406. [Google Scholar] [CrossRef] [PubMed]
- Suissa, S.; Patenaude, V.; Lapi, F.; Ernst, P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013, 68, 1029–1036. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aksoy, M.O.; Li, X.; Borenstein, M.; Yi, Y.; Kelsen, S.G. Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells. J. Allergy Clin. Immunol. 1999, 103, 1081–1091. [Google Scholar] [CrossRef]
- Hirata, F.; Schiffmann, E.; Venkatasubramanian, K.; Salomon, D.; Axelrod, J. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc. Natl. Acad. Sci. USA 1980, 77, 2533–2536. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hermoso, M.A.; Cidlowski, J.A. Putting the brake on inflammatory responses: The role of glucocorticoids. IUBMB Life 2003, 55, 497–504. [Google Scholar] [CrossRef] [PubMed]
- Ericson-Neilsen, W.; Kaye, A.D. Steroids: Pharmacology, complications, and practice delivery issues. Ochsner J. 2014, 14, 203–207. [Google Scholar]
- Williams, D.M. Clinical Pharmacology of Corticosteroids. Respir. Care 2018, 63, 655–670. [Google Scholar] [CrossRef] [Green Version]
- Malcher-Lopes, R.; Franco, A.; Tasker, J.G. Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: A non-genomic anti-inflammatory switch. Eur. J. Pharmacol. 2008, 583, 322–339. [Google Scholar] [CrossRef] [Green Version]
- Young, R.P.; Hopkins, R.J. Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities. Expert Rev. Respir. Med. 2013, 7, 533–544. [Google Scholar] [CrossRef]
- Young, R.P.; Hopkins, R.; Eaton, T.E. Pharmacological actions of statins: Potential utility in COPD. Eur. Respir. Rev. 2009, 18, 222–232. [Google Scholar] [CrossRef] [Green Version]
- Walsh, A.; Perrem, L.; Khashan, A.S.; Henry, M.T.; Ni Chroinin, M. Statins versus placebo for people with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2019, 7, CD011959. [Google Scholar] [CrossRef] [PubMed]
- Rezk, N.A.; Elewa, A. Anti inflammatory effects of statin in COPD. Egypt. J. Chest Dis. Tuberc. 2013, 62, 65–69. [Google Scholar] [CrossRef] [Green Version]
- Damkjaer, M.; Hakansson, K.; Kallemose, T.; Ulrik, C.S.; Godtfredsen, N. Statins in High-Risk Chronic Obstructive Pulmonary Disease Outpatients: No Impact on Time to First Exacerbation and All-Cause Mortality—The STATUETTE Cohort Study. Int. J. Chronic Obs. Pulm. Dis. 2021, 16, 579–589. [Google Scholar] [CrossRef] [PubMed]
- Raymakers, A.J.N.; Sadatsafavi, M.; Sin, D.D.; De Vera, M.A.; Lynd, L.D. The Impact of Statin Drug Use on All-Cause Mortality in Patients With COPD: A Population-Based Cohort Study. Chest 2017, 152, 486–493. [Google Scholar] [CrossRef]
- Lu, Y.; Chang, R.; Yao, J.; Xu, X.; Teng, Y.; Cheng, N. Effectiveness of long-term using statins in COPD—A network meta-analysis. Respir. Res. 2019, 20, 17. [Google Scholar] [CrossRef]
- Lin, C.M.; Yang, T.M.; Yang, Y.H.; Tsai, Y.H.; Lee, C.P.; Chen, P.C.; Chen, W.C.; Hsieh, M.J. Statin Use and the Risk of Subsequent Hospitalized Exacerbations in COPD Patients with Frequent Exacerbations. Int. J. Chronic Obs. Pulm. Dis. 2020, 15, 289–299. [Google Scholar] [CrossRef] [Green Version]
- Cao, C.; Wu, Y.; Xu, Z.; Lv, D.; Zhang, C.; Lai, T.; Li, W.; Shen, H. The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality: A systematic review and meta-analysis of observational research. Sci. Rep. 2015, 5, 16461. [Google Scholar] [CrossRef] [Green Version]
- Ingebrigtsen, T.S.; Marott, J.L.; Nordestgaard, B.G.; Lange, P.; Hallas, J.; Vestbo, J. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax 2015, 70, 33–40. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, Y.J.; Kao, S.; Kao, L.T.; Chian, C.F.; Chung, C.H.; Chien, W.C.; Wang, K.Y. Association Between Statin Use and Exacerbation of Chronic Obstructive Pulmonary Disease Among Patients Receiving Corticosteroids. IInt. J. Chronic Obs. Pulm. Dis. 2021, 16, 591–602. [Google Scholar] [CrossRef]
- Jin, Y.; Tachibana, I.; Takeda, Y.; He, P.; Kang, S.; Suzuki, M.; Kuhara, H.; Tetsumoto, S.; Tsujino, K.; Minami, T.; et al. Statins decrease lung inflammation in mice by upregulating tetraspanin CD9 in macrophages. PLoS ONE 2013, 8, e73706. [Google Scholar] [CrossRef] [Green Version]
- Ko, H.H.T.; Lareu, R.R.; Dix, B.R.; Hughes, J.D. In vitro antibacterial effects of statins against bacterial pathogens causing skin infections. Eur. J. Clin. Microbiol. Infect. Dis. 2018, 37, 1125–1135. [Google Scholar] [CrossRef] [PubMed]
- Fu, H.; Alabdullah, M.; Großmann, J.; Spieler, F.; Abdosh, R.; Lutz, V.; Kalies, K.; Knöpp, K.; Rieckmann, M.; Koch, S.; et al. The differential statin effect on cytokine production of monocytes or macrophages is mediated by differential geranylgeranylation-dependent Rac1 activation. Cell Death Dis. 2019, 10, 880. [Google Scholar] [CrossRef] [Green Version]
- Masadeh, M.; Mhaidat, N.; Alzoubi, K.; Al-Azzam, S.; Alnasser, Z. Antibacterial activity of statins: A comparative study of atorvastatin, simvastatin, and rosuvastatin. Ann. Clin. Microbiol. Antimicrob. 2012, 11, 13. [Google Scholar] [CrossRef] [Green Version]
- Hennessy, E.; O’Callaghan, J.; Mooij, M.J.; Legendre, C.; Camacho-Vanegas, O.; Camacho, S.C.; Adams, C.; Martignetti, J.A.; O’Gara, F. The impact of simvastatin on pulmonary effectors of Pseudomonas aeruginosa infection. PLoS ONE 2014, 9, e102200. [Google Scholar] [CrossRef] [Green Version]
- Feng, L.; Zhou, L.; Sun, Y.; Gui, J.; Wang, X.; Wu, P.; Wan, J.; Ren, Y.; Qiu, S.; Wei, X.; et al. Specific inhibitions of annonaceous acetogenins on class II 3-hydroxy-3-methylglutaryl coenzyme A reductase from Streptococcus pneumoniae. Bioorg. Med. Chem. 2011, 19, 3512–3519. [Google Scholar] [CrossRef]
- Galiullina, L.F.; Scheidt, H.A.; Huster, D.; Aganov, A.; Klochkov, V. Interaction of statins with phospholipid bilayers studied by solid-state NMR spectroscopy. Biochim. Biophys. Acta BBA Biomembr. 2019, 1861, 584–593. [Google Scholar] [CrossRef] [PubMed]
- Zaborowska, M.; Broniatowski, M.; Wydro, P.; Matyszewska, D.; Bilewicz, R. Structural modifications of lipid membranes exposed to statins—Langmuir monolayer and PM-IRRAS study. J. Mol. Liq. 2020, 313, 113570. [Google Scholar] [CrossRef]
Lipids | Disorders That Occur during Smoking and COPD | Processes Affected by Lipid Metabolism Disorders | References | |
---|---|---|---|---|
Fatty acids | Disorders in the ratio of saturated and unsaturated fatty acids in the composition of membrane phospholipids; | activation and resolution of inflammation (lipid mediators of inflammation); activation of TLR4 signaling; | [20,28,29,30,32,33,34,35,38,39,40,41,42,43,52,95,96,108,234,235,236] | |
change in the amount of free fatty acids; | immuno-metabolism of macrophages (fatty acid oxidation) | |||
fatty acid oxidation disorders | ||||
Phospholipids | Disorders in the ratio of saturated and unsaturated fatty acids in the composition of membrane phospholipids | the fluidity and permeability of plasma membranes; | [19,24,38,39,40,51,52,234,235,236,237] | |
participation in ensuring the structure and function of the plasma membrane; | ||||
organization of lipid rafts; | ||||
regulation of the membrane protein function, including those associated with inflammation; | ||||
participation in phagocytosis | ||||
Sphingolipids | Smokers and patients with COPD have elevated levels of ceramides in the lungs | increased structural apoptosis; | [19,20,21,24,35,99,100,101,102,103,104,105,106,107,109,110,176,177,178] | |
activation of TLR4 signaling; | ||||
organization of lipid rafts, reorganization of lipid rafts enriched with ceramide | ||||
Cholesterol | Disorders of reverse transport of cholesterol from macrophages during smoking and COPD | participation in ensuring the structure and function of the plasma membrane; | [19,48,49,50,67,68,82,90,91,92,231] | |
organization of lipid rafts; | ||||
regulation of the function of membrane proteins, including those associated with inflammation; | ||||
phagocytosis disorders |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kotlyarov, S.; Kotlyarova, A. Molecular Mechanisms of Lipid Metabolism Disorders in Infectious Exacerbations of Chronic Obstructive Pulmonary Disease. Int. J. Mol. Sci. 2021, 22, 7634. https://doi.org/10.3390/ijms22147634
Kotlyarov S, Kotlyarova A. Molecular Mechanisms of Lipid Metabolism Disorders in Infectious Exacerbations of Chronic Obstructive Pulmonary Disease. International Journal of Molecular Sciences. 2021; 22(14):7634. https://doi.org/10.3390/ijms22147634
Chicago/Turabian StyleKotlyarov, Stanislav, and Anna Kotlyarova. 2021. "Molecular Mechanisms of Lipid Metabolism Disorders in Infectious Exacerbations of Chronic Obstructive Pulmonary Disease" International Journal of Molecular Sciences 22, no. 14: 7634. https://doi.org/10.3390/ijms22147634
APA StyleKotlyarov, S., & Kotlyarova, A. (2021). Molecular Mechanisms of Lipid Metabolism Disorders in Infectious Exacerbations of Chronic Obstructive Pulmonary Disease. International Journal of Molecular Sciences, 22(14), 7634. https://doi.org/10.3390/ijms22147634